<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7252421\results\search\testTrace\results.xml">
  <result pre="have dyspnea and fatigue as leading symptoms, prevention, diagnostics and" exact="treatment" post="in these patients are important to provide adequate care"/>
  <result pre="cardiovascular and pulmonary protection, there is ongoing discussions on whether" exact="treatment" post="with cardiovascular drugs, which upregulate the viral receptor ACE2"/>
  <result pre="general, three distinct phases characterize progression of COVID-19: an initial" exact="infection" post="phase followed by a respiratory distress phase and finally"/>
  <result pre="as a primary target as well as a comorbidity. The" exact="infection" post="phase marks virus infiltration and proliferation of the epithelium"/>
  <result pre="the heart itself might be a direct target for viral" exact="infection" post="with SARS-CoV-2 [5]. Previous studies examining the cardiovascular effects"/>
  <result pre="play a pivotal role for the deleterious consequences of SARS-CoV-2" exact="infection" post="in addition to the severe acute respiratory distress syndrome"/>
  <result pre="distress syndrome (ARDS). Fig. 1 Summary of consequences of SARS-Cov2" exact="infection" post="on the cardiovascular system summarizing primary targets (left) and"/>
  <result pre="may also be more vulnerable to adverse cardiotoxic effects of" exact="treatment" post="with antiviral drugs. A most recent analysis from the"/>
  <result pre="most recent analysis from the LEOSS registry [12] displaying the" exact="prevalence" post="of co-morbidities in COVID-19 patients in Germany disclosed that"/>
  <result pre="decompensated heart failure or life-threatening arrhythmias need immediate attention and" exact="treatment" post="and emergency calls should not be delayed out of"/>
  <result pre="potential to acquire COVID-19. We do need to set-up emergency" exact="treatment" post="strategies for non-COVID-19 patients in-hospital and assure protection of"/>
  <result pre="viral RNA is released into this cellular cytoplasm causing SARS" exact="infection" post="[28, 29]. ACE2 is degraded and shedfrom the cell"/>
  <result pre="virus itself [31]. The role of ACE2 in CORONA virus" exact="infection" post="is scrutinized by the fact that several animals cannot"/>
  <result pre="is a knockout of ACE2, which renders them resistant to" exact="infection" post="[32]. The role of ACE2 is not specific for"/>
  <result pre="it might also mediate beneficial effects on pulmonary complications after" exact="infection" post="[36, 37]. The fact that the major risk factor"/>
  <result pre="age [17]. On the contrary, membrane-bound ACE2-concentrations are higher following" exact="treatment" post="with ACE-inhibitors, AT1-blockers and potentially ibuprofen, and ACE2 is"/>
  <result pre="mediating anti-proliferative, anti-inflammatory action, hypothetically enhanced ACE2-expression might cause more" exact="infection" post="by acting as a receptor for viral cell entry"/>
  <result pre="pulmonary complications. In conditions where is downregulation of ACE2, less" exact="infection" post="might occur, but severity of COVID-19-related ARDS can be"/>
  <result pre="malignancies [9]. As hypertension is the comorbidity with the highest" exact="prevalence" post="in deceased patients, it has been claimed to be"/>
  <result pre="the case, if there is a deviation from the overall" exact="prevalence" post="of hypertension in the Chinese population. In China, the"/>
  <result pre="prevalence of hypertension in the Chinese population. In China, the" exact="prevalence" post="of hypertension is high. By comparing Chinese populations age-matched"/>
  <result pre="COVID-19 (approximately 55â€&quot;74Â years), it becomes clear that the overall" exact="prevalence" post="in hypertension is 44% with a further increase in"/>
  <result pre="further increase in populations at higher age [48]. Therefore, the" exact="prevalence" post="of the comorbidity hypertension in COVID-19 patients is lower"/>
  <result pre="COVID-19 patients is lower and does not exceed the overall" exact="prevalence" post="in the relevant populations in China. Therefore, there is"/>
  <result pre="Heart Association (AHA) [19] recommend ACE and ARBs for the" exact="treatment" post="of hypertension as these drugs have been shown to"/>
  <result pre="2017 ACC/AHA guidelines [19]. In particular, the frequency of ACE-inhibitor" exact="treatment" post="is particularly low in an Asian population (in particular"/>
  <result pre="than in other populations [51]. Therefore, the low density of" exact="treatment" post="with RASi does not argue in favor of a"/>
  <result pre="are necessary to scrutinize the definite role of ACE2 in" exact="infection" post="frequency and causation of pulmonary complications after CORONA infections."/>
  <result pre="conditions. COVID-19 and myocardial injury The cardiac manifestations of SARS-CoV-2" exact="infection" post="include acute myocardial injury, heart failure, myocarditis, and ventricular"/>
  <result pre="death [9]. In a cohort of 416 hospitalized patients, the" exact="prevalence" post="of cardiac injury-based on the presence of elevated hs-cTnI"/>
  <result pre="reference value of hs-TnI [9]. Unequivocally, other cohorts investigating the" exact="prevalence" post="and prognostic implications of myocardial injury during the COVID-19"/>
  <result pre="acute myocardial injury might be triggered or facilitated in COVID-19" exact="infection" post="[59, 66]. A previous study on the incidence of"/>
  <result pre="was hypothesized that an exaggerated inflammatory response mediated by viral" exact="infection" post="with Influenza A or B, respiratory syncytial virus (RSV)"/>
  <result pre="the absence of histological confirmation by endocardial biopsy, or by" exact="detection" post="of viral genome in myocardial tissue, yet [67]. Previously,"/>
  <result pre="diastolic left ventricular impairment that was reported in acute SARS-CoV-2" exact="infection" post="and was attributed to the cytokine storm syndrome that"/>
  <result pre="is lacking. Given the paucity of data on the exact" exact="prevalence" post="and reasons for an acute myocardial injury during COVID-19,"/>
  <result pre="sepsis and 64.1Â ng/L in septic shock [70]. Likewise, the" exact="prevalence" post="of hs-cTnTâ€‰&amp;gt;â€‰ULN increased from 51.6% in sepsis to 80.4%"/>
  <result pre="and potential pathomechanisms of release of cardiac troponin during COVID-19" exact="infection" post="Practical considerations for patients presenting with suspected or confirmed"/>
  <result pre="Practical considerations for patients presenting with suspected or confirmed COVID-19" exact="infection" post="and suspected Type I Myocardial Infarction (T1MI) Acute MI"/>
  <result pre="cardiovascular comorbidities [7, 93]. Yet, likely due to the lower" exact="prevalence" post="of (known) CHF in China, there is still limited"/>
  <result pre="cytokines (â€œcytokine stormâ€�). ACE2 as a potential receptor for Coronavirus" exact="infection" post="(s. above) is highly expressed in cardiomyocytes and in"/>
  <result pre="also revealed myocardial injury with increased high sensitive troponin. Specific" exact="treatment" post="of the â€œcytokine stormâ€� and heart failure in COVID-19?"/>
  <result pre="in China: data from 1Â·7 million adults in a population-based" exact="screening" post="study (China PEACE Million Persons Project)Lancet20173902549255829102084 52.KusterGMPfisterOBurkardTZhouQTwerenboldRHaafPWidmerAFOsswaldSSARS-CoV2: should inhibitors"/>
  <result pre="in patients with COVID-19?Eur Heart J202010.1093/eurheartj/ehaa23532432723 53.BavishiCMaddoxTMMesserliFHCoronavirus Disease 2019 (COVID-19)" exact="infection" post="and renin angiotensin system blockersJAMA Cardiol202010.1001/jamacardio.2020.128232242890 54.PatelABVermaACOVID-19 and angiotensin-converting"/>
  <result pre="SARS-CoV-2J Med Virol202010.1002/jmv.2572332427358 76.AiTYangZHouHet al.Correlation of chest CT and RT-PCR" exact="testing" post="in Coronavirus Disease 2019 (COVID-19) in China: a report"/>
  <result pre="reanalysis of a prior phase III trialCrit Care Med201644227528110.1097/CCM.000000000000140226584195 102.XuXHanMLiTSunWWangDFuBZhouYZhengXYangYLiXZhangXPanAWeiHEffective" exact="treatment" post="of severe COVID-19 patients with tocilizumabPNAS202010.1073/pnas.200561511732434921 103.FavalliEGBiggioggeroMMaioliGCaporaliRBaricitinib for COVID-19:"/>
 </snippets>
</snippetsTree>
